⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151544 | 1.00 | — | — | |
| SCHEMBL12535915 | 1.00 | — | — | |
| SCHEMBL43516 | 1.00 | — | — | |
| SCHEMBL735479 | 1.00 | — | — | |
| SCHEMBL10151561 | 1.00 | — | — | |
| SCHEMBL735480 | 1.00 | — | — | |
| SCHEMBL896134 | 1.00 | — | — | |
| SCHEMBL12439901 | 1.00 | — | — | |
| SCHEMBL24744320 | 0.97 | THRB (0.53) | — | |
| SCHEMBL21251132 | 0.97 | THRB (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | claimed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | claimed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | claimed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| CN-119023611-A | Real-time monitoring method for ketone-amine conversion reaction process and application thereof | 北京衍微科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11701354-B2 | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-7166602-B2 | Pyrazolotriazines as kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070015924-A1 | Synthetic processes for the preparation of aminocyclohexyl ether compounds | CARDIOME PHARMA CORP. (CA) | 2007-01-18 | — | — | US | disclosed |
| US-4851534-A | ENANTIOSELECTIVE HYDROGENATION CATALYST | CIBA-GEIGY CORPORATION (US) | 1989-07-25 | — | — | US | disclosed |